ANAPTYSBIO, INC. Investing Cash Flow
ANAPTYSBIO, INC. (ANAB) reported Investing Cash Flow of $42.55 million for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-09-21
- ANAPTYSBIO, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $7.56M, a 91.79% decline year-over-year.
- ANAPTYSBIO, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $34.98M, a 135.62% increase year-over-year.
- ANAPTYSBIO, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $73.50M.
- ANAPTYSBIO, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $47.58M, a 18.83% decline year-over-year.
- ANAPTYSBIO, INC. net cash provided by (used in) investing activities for fiscal 2025 was $228.03M, a 627.07% increase from fiscal 2024.
- ANAPTYSBIO, INC. net cash provided by (used in) investing activities for fiscal 2024 was $31.36M, a 78.33% decline from fiscal 2023.
- ANAPTYSBIO, INC. net cash provided by (used in) investing activities for fiscal 2023 was $144.75M.
- ANAPTYSBIO, INC. net cash provided by (used in) investing activities for fiscal 2022 was -$394.85M, a 1116.72% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 6 month as first filed | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month | Net Cash Provided by (Used in) Investing Activities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7.56M derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | $42.55M 10-KT · filed 2026-09-21 | $116.05M derived: sum of 3 quarters · filed 2026-09-21 | $163.63M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2026-03-31 | $34.98M 10-Q · filed 2026-05-12 | $108.48M derived: sum of 2 quarters · filed 2026-09-21 | $156.06M derived: sum of 3 quarters · filed 2026-09-21 | $248.17M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2025-12-31 | $73.50M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $121.08M derived: sum of 2 quarters · filed 2026-09-21 | $213.19M derived: sum of 3 quarters · filed 2026-09-21 | $228.03M 10-KT · filed 2026-09-21 | ||
| 2025-09-30 | $47.58M derived: 10-Q 9 month − 10-KT 6 month · filed 2025-11-04 | $139.69M derived: sum of 2 quarters · filed 2026-09-21 | $154.53M 10-Q · filed 2025-11-04 | $61.10M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2025-06-30 | $92.11M derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | $106.95M 10-KT · filed 2026-09-21 | $51.25M 10-Q · filed 2025-08-06 | $13.52M derived: sum of 3 quarters · filed 2026-09-21 | $72.14M derived: sum of 4 quarters · filed 2026-09-21 | |
| 2025-03-31 | $14.85M 10-Q · filed 2026-05-12 | -$78.58M derived: sum of 2 quarters · filed 2026-09-21 | -$19.96M derived: sum of 3 quarters · filed 2026-09-21 | -$22.41M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2024-12-31 | -$93.43M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | -$34.81M derived: sum of 2 quarters · filed 2026-09-21 | -$37.25M derived: sum of 3 quarters · filed 2026-09-21 | $31.36M 10-KT · filed 2026-09-21 | $95.40M 10-K · filed 2025-02-27 | |
| 2024-09-30 | $58.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $56.18M derived: sum of 2 quarters · filed 2025-11-04 | $124.79M 10-Q · filed 2025-11-04 | $173.97M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-06-30 | -$2.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $66.17M 10-Q · filed 2025-08-06 | $115.35M derived: sum of 3 quarters · filed 2026-03-03 | $145.99M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-03-31 | $68.62M 10-Q · filed 2025-05-05 | $117.79M derived: sum of 2 quarters · filed 2026-03-03 | $148.43M derived: sum of 3 quarters · filed 2026-03-03 | $127.97M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2023-12-31 | $49.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $79.81M derived: sum of 2 quarters · filed 2026-03-03 | $59.36M derived: sum of 3 quarters · filed 2026-03-03 | $144.75M 10-K · filed 2026-03-03 | ||
| 2023-09-30 | $30.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $10.18M derived: sum of 2 quarters · filed 2024-11-05 | $95.58M 10-Q · filed 2024-11-05 | $117.07M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | -$20.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $64.94M 10-Q · filed 2024-08-05 | $86.44M derived: sum of 3 quarters · filed 2025-02-27 | $54.00M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | $85.40M 10-Q · filed 2024-05-09 | $106.89M derived: sum of 2 quarters · filed 2025-02-27 | $74.46M derived: sum of 3 quarters · filed 2025-02-27 | $3.46M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2022-12-31 | $21.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$10.94M derived: sum of 2 quarters · filed 2025-02-27 | -$81.93M derived: sum of 3 quarters · filed 2025-02-27 | -$394.85M 10-K · filed 2025-02-27 | ||
| 2022-09-30 | -$32.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$103.43M derived: sum of 2 quarters · filed 2023-11-02 | -$416.34M 10-Q · filed 2023-11-02 | -$483.04M derived: sum of 4 quarters · filed 2024-03-11 | ||
| 2022-06-30 | -$71.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$383.91M 10-Q · filed 2023-08-07 | -$450.60M derived: sum of 3 quarters · filed 2024-03-11 | -$439.76M derived: sum of 4 quarters · filed 2024-03-11 | ||
| 2022-03-31 | -$312.91M 10-Q · filed 2023-05-11 | -$379.61M derived: sum of 2 quarters · filed 2024-03-11 | -$368.77M derived: sum of 3 quarters · filed 2024-03-11 | -$330.81M derived: sum of 4 quarters · filed 2024-03-11 | ||
| 2021-12-31 | -$66.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$55.85M derived: sum of 2 quarters · filed 2024-03-11 | -$17.89M derived: sum of 3 quarters · filed 2024-03-11 | $38.84M 10-K · filed 2024-03-11 | ||
| 2021-09-30 | $10.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $48.80M derived: sum of 2 quarters · filed 2022-11-08 | $105.53M 10-Q · filed 2022-11-08 | $109.13M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-06-30 | $37.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $94.69M 10-Q · filed 2022-08-08 | $98.29M derived: sum of 3 quarters · filed 2023-03-01 | $103.02M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-03-31 | $56.73M 10-Q · filed 2022-05-04 | $60.33M derived: sum of 2 quarters · filed 2023-03-01 | $65.06M derived: sum of 3 quarters · filed 2023-03-01 | $140.45M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2020-12-31 | $3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $8.33M derived: sum of 2 quarters · filed 2023-03-01 | $83.72M derived: sum of 3 quarters · filed 2023-03-01 | $94.47M 10-K · filed 2023-03-01 | ||
| 2020-09-30 | $4.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $80.13M derived: sum of 2 quarters · filed 2021-11-04 | $90.88M 10-Q · filed 2021-11-04 | $94.91M derived: sum of 4 quarters · filed 2022-03-07 | ||
| 2020-06-30 | $75.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $86.14M 10-Q · filed 2021-08-09 | $90.18M derived: sum of 3 quarters · filed 2022-03-07 | $150.04M derived: sum of 4 quarters · filed 2022-03-07 | ||
| 2020-03-31 | $10.75M 10-Q · filed 2021-05-04 | $14.79M derived: sum of 2 quarters · filed 2022-03-07 | $74.65M derived: sum of 3 quarters · filed 2022-03-07 | $132.53M derived: sum of 4 quarters · filed 2022-03-07 | ||
| 2019-12-31 | $4.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $63.90M derived: sum of 2 quarters · filed 2022-03-07 | $121.77M derived: sum of 3 quarters · filed 2022-03-07 | $131.43M 10-K · filed 2022-03-07 | ||
| 2019-09-30 | $59.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $117.74M derived: sum of 2 quarters · filed 2020-11-04 | $127.40M 10-Q · filed 2020-11-04 | -$38.75M derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2019-06-30 | $57.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $67.53M 10-Q · filed 2020-08-10 | -$98.62M derived: sum of 3 quarters · filed 2021-02-25 | -$74.00M derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2019-03-31 | $9.66M 10-Q · filed 2020-05-06 | -$156.49M derived: sum of 2 quarters · filed 2021-02-25 | -$131.88M derived: sum of 3 quarters · filed 2021-02-25 | -$134.94M derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2018-12-31 | -$166.15M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$141.53M derived: sum of 2 quarters · filed 2021-02-25 | -$144.60M derived: sum of 3 quarters · filed 2021-02-25 | -$142.45M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $24.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $21.55M derived: sum of 2 quarters · filed 2019-11-08 | $23.70M 10-Q · filed 2019-11-08 | -$129.36M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-06-30 | -$3.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$916.00K 10-Q · filed 2019-08-08 | -$153.97M derived: sum of 3 quarters · filed 2020-03-02 | -$154.47M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-03-31 | $2.15M 10-Q · filed 2019-05-07 | -$150.91M derived: sum of 2 quarters · filed 2020-03-02 | -$151.41M derived: sum of 3 quarters · filed 2020-03-02 | -$213.83M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2017-12-31 | -$153.06M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$153.55M derived: sum of 2 quarters · filed 2020-03-02 | -$215.97M derived: sum of 3 quarters · filed 2020-03-02 | -$243.06M 10-K · filed 2020-03-02 | ||
| 2017-09-30 | -$495.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$62.92M derived: sum of 2 quarters · filed 2018-11-08 | -$90.00M 10-Q · filed 2018-11-08 | -$90.00M derived: sum of 4 quarters · filed 2019-02-28 | ||
| 2017-06-30 | -$62.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$89.51M 10-Q · filed 2018-08-07 | -$89.51M derived: sum of 3 quarters · filed 2019-02-28 | -$89.51M derived: sum of 4 quarters · filed 2019-02-28 | ||
| 2017-03-31 | -$27.09M 10-Q · filed 2018-05-08 | -$27.09M derived: sum of 2 quarters · filed 2019-02-28 | -$27.09M derived: sum of 3 quarters · filed 2019-02-28 | -$27.10M derived: sum of 4 quarters · filed 2019-02-28 | ||
| 2016-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | -$1.00K derived: sum of 2 quarters · filed 2019-02-28 | -$15.00K derived: sum of 3 quarters · filed 2019-02-28 | -$50.00K 10-K · filed 2019-02-28 | ||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$14.00K derived: sum of 2 quarters · filed 2017-11-07 | -$49.00K 10-Q · filed 2017-11-07 | |||
| 2016-06-30 | -$14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | -$49.00K 10-Q · filed 2017-08-10 | ||||
| 2016-03-31 | -$35.00K 10-Q · filed 2017-05-12 | |||||
| 2015-12-31 | -$238.00K 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |